Korro Bio, Inc. (KRRO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $186.81M
Last updated: Nov 17, 2026 at 11:06 AM ET
Korro Bio, Inc. (KRRO) Stock Forecast
Analysts expect Korro Bio (KRRO) to earn -$4.68 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.31M. Of 11 analysts, 10 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.91, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 91% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 18.2% |
| Buy | 8 | 72.7% |
| Hold | 1 | 9.1% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 11
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates fall 65.6%.
- Fiscal year ending Dec 31, 2026
- -$4.68
- EPS consensus, revenue $1.31M
- Fiscal year ending Dec 31, 2027
- -$4.25
- EPS consensus, revenue $450000
- Next report
- Mar 10, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$4.68 | -$5.87 to -$4.26 | 9 | $1.31M | N/A | 6 |
| Dec 31, 2027 | -$4.25 | -$5.03 to -$3.39 | 8 | $450000 | N/A | 6 |
Quarterly Estimates
The EPS consensus rises from -$1.38 for the quarter ending Dec 31, 2026 to -$1.03 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$1.38 | -$2.39 to -$0.62 | 14 | $2.19M | N/A | 12 |
| Mar 31, 2027 | -$1.03 | -$1.25 to -$0.80 | 6 | $125000 | N/A | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$5.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$4.68 | -$5.23 | -$5.23 | -$5.18 | -$5.18 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.25 | -$4.42 | -$4.42 | -$4.46 | -$4.46 | N/A |
| Quarter ending Mar 31, 2027 | -$1.03 | -$1.04 | -$1.04 | -$1.04 | -$1.04 | N/A |
Frequently Asked Questions About KRRO
What is the KRRO stock forecast?
Consensus analyst estimates put Korro Bio's EPS at -$4.68 for the fiscal year ending Dec 31, 2026, on revenue of $1.31M. The consensus rating from 11 analysts is Buy.
How do analysts rate KRRO stock?
Of 11 analysts covering Korro Bio, 2 rate it Strong Buy, 8 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KRRO next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$4.68, with estimates from -$5.87 to -$4.26 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.25, with estimates from -$5.03 to -$3.39 from 8 analysts.
What revenue do analysts expect from Korro Bio next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.31M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $450000.
How many analysts cover KRRO?
11 analysts rate Korro Bio stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KRRO pages: Overview, Earnings, Forecast, Financials, Competitors